233 related articles for article (PubMed ID: 25086226)
1. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
2. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
[TBL] [Abstract][Full Text] [Related]
3. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
4. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
5. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays.
Mata MM; Mahmood F; Sowell RT; Baum LL
J Immunol Methods; 2014 Apr; 406():1-9. PubMed ID: 24561308
[TBL] [Abstract][Full Text] [Related]
6. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
Schlaeth M; Berger S; Derer S; Klausz K; Lohse S; Dechant M; Lazar GA; Schneider-Merck T; Peipp M; Valerius T
Cancer Sci; 2010 May; 101(5):1080-8. PubMed ID: 20331636
[TBL] [Abstract][Full Text] [Related]
7. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
8. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
9. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
[TBL] [Abstract][Full Text] [Related]
11. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.
Bier H; Hoffmann T; Haas I; van Lierop A
Cancer Immunol Immunother; 1998 May; 46(3):167-73. PubMed ID: 9625540
[TBL] [Abstract][Full Text] [Related]
12. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
13. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.
Awwad M; Strome PG; Gilman SC; Axelrod HR
Cancer Immunol Immunother; 1994 Jan; 38(1):23-30. PubMed ID: 8299115
[TBL] [Abstract][Full Text] [Related]
14. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.
Yu M; Brown D; Reed C; Chung S; Lutman J; Stefanich E; Wong A; Stephan JP; Bayer R
MAbs; 2012; 4(4):475-87. PubMed ID: 22699308
[TBL] [Abstract][Full Text] [Related]
15. Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1.
Lewis GK; Ackerman ME; Scarlatti G; Moog C; Robert-Guroff M; Kent SJ; Overbaugh J; Reeves RK; Ferrari G; Thyagarajan B
Front Immunol; 2019; 10():1025. PubMed ID: 31134085
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
Kimura H; Sakai K; Arao T; Shimoyama T; Tamura T; Nishio K
Cancer Sci; 2007 Aug; 98(8):1275-80. PubMed ID: 17498200
[TBL] [Abstract][Full Text] [Related]
17. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
[TBL] [Abstract][Full Text] [Related]
18. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
19. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
[TBL] [Abstract][Full Text] [Related]
20. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery.
Sturniolo I; Váróczy C; Bede ÁM; Hegedűs C; Demény MÁ; Virág L
J Vis Exp; 2024 Apr; (206):. PubMed ID: 38738886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
